COVID-19 Neutralizing Antibody Rapid Test Kit (Colloidal Gold)

ʻO ka wehewehe pōkole:

Huahana Huahana

Manaʻo e hoʻohana:

◆No ka ʻike ʻana i nā antibodies neutralizing.

◆COVID-19 Neutralizing Antibody Rapid Test Kit (Colloidal Gold) he lateral flow immunoassay i manaʻo no ka ʻike qualitative o neutralizing antibody o SARS-CoV-2 i loko o ke koko holoʻokoʻa o ke kanaka, serum a i ʻole ka plasma ma ke ʻano he kōkua i nā pae loiloi o ke kanaka anti. -novel coronavirus neutralizing antibody titer.

ʻano laʻana

◆Koko holoʻokoʻa, Serum, Plasma

Kuʻuna Hana:

◆Hoʻohana kēia kime i ka immunochromatography.Aia i loko o ke kāleka hoʻāʻo: 1) colloidal gold-labeled recombinant novel coronavirus S-RBD antigen a me nā māka gula antibody control quality;2) hoʻokahi laina ʻike (laina T) a me kahi laina Mana maikaʻi (laina C) o ka membrane nitrocellulose.Hoʻopili ʻia ka laina T me ka protein Human ACE2 no ka ʻike ʻana i ka novel coronavirus neutralizing antibody a ʻo ka laina C i immobilized me kahi antibody control quality.

◆Ke hoʻohui ʻia ka nui kūpono o ka hāpana hoʻāʻo i ka lua hāpana o ke kāleka hoʻāʻo, e neʻe ka hāpana i mua ma ke kāleka hoʻāʻo ma lalo o ka hana o ka capillary.Inā loaʻa i ka laʻana ka novel coronavirus neutralizing antibody, e hoʻopaʻa ka antibody i ka colloidal gold-labeled novel coronavirus antigen.ʻO ke koena o ka coronavirus antigen i hoʻopaʻa inoa ʻia i ke gula i loko o ka paʻakikī immune e hopu ʻia e ka protein ACE2 kanaka i hoʻopaʻa ʻia ma luna.

ʻO ka membrane e hana i kahi laina T poni-ʻulaʻula, ka ikaika o ka laina T i hoʻohālikelike ʻia me ka neʻe ʻana o ka antibody.

◆Aia i loko o ke kāleka ho'āʻo kahi laina hoʻomalu maikaʻi C. Pono e ʻike ʻia ka laina hoʻokele maikaʻi o fuchsia C me ka nānā ʻole inā ʻike ʻia kahi laina hoʻāʻo.Inā ʻaʻole ʻike ʻia ka laina hoʻokele maikaʻi C, ʻaʻole kūpono ka hopena hōʻike, a pono e hoʻāʻo hou ʻia ka hāpana me kahi kāleka hōʻike ʻē aʻe.

kikoʻī huahana:

◆Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, a i ʻole 2019-nCoV) he maʻi RNA i hoʻopaʻa ʻia i hoʻokaʻawale ʻole ʻia.ʻO ia ka

ke kumu o COVID-19, ka mea lele i loko o ke kanaka.

◆SARS-CoV-2 loaʻa i kekahi mau mea hoʻolalelale e pili ana i ka spike (S), envelope (E), membrane (M) a me ka nucleocapsid (N).Aia ka spike protein (S) i kahi receptor binding domain (RBD), nona ke kuleana no ka ʻike ʻana i ka cell surface receptor, antigens i ka hoʻololi ʻana i ka enzyme-2 (ACE2).Loaʻa ʻia ka mea hoʻokipa ACE2 kanaka e alakaʻi ana i ka endocytosis i loko o nā keʻena hoʻokipa o ka hohonu hohonu a me ka replication viral.

◆ ʻO ka maʻi me ka SARS-CoV-2 a i ʻole SARS-COV-2 Vaccine ka hoʻomaka ʻana i ka pane kūlohelohe e hana i nā antibodies e hāʻawi i ka pale i nā maʻi e hiki mai ana mai nā maʻi.ʻO nā antibodies neutralizing kanaka e kuhikuhi ana i ka host ACE2 receptor-binding domain (RBD) o ka SAR-COV-2 spike protein e hōʻike ana i ka hoʻohiki ʻana i ka therapeutically a me ka hana palekana.

◆Serum a i ʻole plasma specimen/koko manamana lima.

◆No ka ʻike semi-quantitative o neutralizing antibody.

◆Hiki i ka hoʻāʻo ʻana i ka antibody ke ʻike inā aia nā antibodies neutralizing e kūʻē i ka SARS-CoV-2 i loko o ke kino.

◆E kōkua i ka nānā ʻana i ka lōʻihi o ka ola ʻana o ka pale pale ma hope o ka hoʻopaʻa ʻana.